Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Opdivo demonstrated significant overall survival benefit over chemotherapy alone in both PD-L1 positive and all-randomized populations in both treatment armsCheckMate -648 marks the third global trial in which Opdivo demonstrated a significant benefit for patients with upper gastrointestinal cancersData to be featur.
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo plus Yervoy for Treatment of Mismatch Repair Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer After Prior Chemotherapy investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years Dual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histology Data to be featured in an oral presentation during … Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs. chemotherapy at two years Dual immunotherapy-based combination demonstrated clinical benefit across key subgroups of patients, regardless of PD-L1 expression level or histology
49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line Opdivo (nivolumab) plus Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with Opdivo plus Yervoy (95% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with